CD161 blockers have been reported to effectively enhance the T cell‐mediated killing of glioma cells and significantly improve antitumor function.[46] GO analyses were performed to investigate the possible biological functions and associated signaling pathways of each T cell subpopulation. The gene discussed is KLRB1; the disease is glioma.